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Objectives: The French “liste-en-sus” was implemented to support an equal access 
to innovative and higly-priced medicines. The methodology to define the scope of 
this list has been updated recently. Listing or delisting is now decided per therapeu-
tic indication and no longer by product. Our aim is to assess the relevance of listed 
therapeutic indications in accordance with the updated methodology. MethOds: 
Using the health technology assessment published by the Transparency Committee, 
we gathered for each medicine included on the liste-en-sus (excluding blood-
derived products) until march 1st, 2015 : assessment date, marketing authorization 
date, medical benefit and improvement in medical benefit (IMB) scores and medi-
cine comparator. We selected therapeutic indications wich fulfilled both criteria : 
no IMB and the comparator is financed by diagnosis-related groups (DRGs). Using 
the French medicalized information system program, we identified International 
classification of diseases (ICD-10) codings groups and we collected expenditures 
corresponding to these indications in France in 2013. Results: The liste-en-sus 
includes 214 indications. IMB is available in 87% of cases. 6% of indications have 
been evaluated before 2005. Another 7% are extensions of indication and they have 
not been assessed yet as marketing authorization has been granted recently. Among 
the 32% of indications showing no IMB, the comparator is financed by DRGs in 7% 
of cases (16 indications or 11 medicines). The 12 ICD-10 codings groups correspond-
ing to these 16 indications show an expenditure of EUR 450.5 million. This amount 
represents 16% of the total expenditures (EUR 2.8 billion) for all medicines included 
on the liste-en-sus in 2013. cOnclusiOns: From now on, all indications including 
extensions of indication have to be evaluated before being registered on the liste-
en-sus by analyzing the health technology assessment published. 16 therapeutic 
indications are not matching the criteria defined in the new methodology.
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PECULIARITY, EnvIROnMEnTAL AnD CHROnIC DISEASES: USIng ECOLOgICAL 
MODELS AS A FRAMEwORk FOR AnALYSISIng RISk FACTORS OF CHROnIC 
DISEASES
Zhu B, Liu J, Wu J, Mao Y
Xi’an Jiaotong University, Xi’an, China
Objectives: With the accelerated aging trend of the population and transforma-
tion of lifestyle, fundamental changes have taken place in disease spectrum of our 
human beings, anda major threat to human health has been gradually shifting 
from infectious diseases to chronic non-communicable diseases. Basing on above, 
an ecological model that derived from Bronfenbrenner’s ecology of human develop-
ment theory was proposed as a theory-based framework to analysis the risk factors 
of chronic diseases. Combined with the characteristics of chronic diseases, as well 
as sociology, policy science and related theory, the ecological model was elaborated 
to personal traits, behavior characteristics, family microsystem, work microsystem 
and the policy environment variables. MethOds: Cross-section data of CHARLS 
(China Health and Retirement Longitudinal Study) 2013 which includes about 10,000 
households and 17,500 individuals in 150 counties/districts and 450 villages/resident 
committees was adopted to conduct the empirical study. Two Methods of regression 
analysis evolved from two-part models and descriptive statistically analysis were 
combined to analysis the effects of different influence factors on the prevalence and 
sicken age. Results: Firstly, personal traits and behavioral characteristics are the 
primary factors which influence the prevalence of chronic diseases; Secondly, family 
microsystem, work microsystem can also have important effects on chronic disease 
prevalence and sicken age; thirdly, financial situation have non-continuous influ-
ence on chronic disease prevalence, which means only low standard of living will 
affect the incidence of chronic diseases. cOnclusiOns: Some effective measures 
should be put forward to improve the chronic disease prevention and control work. 
Firstly, relevant departments should be undertaken by changing health development 
mode and carrying out prevention policy; Secondly, comprehensive intervention 
should be carried out in the community; Thirdly, basic medical insurances for low-
income people to affordable health services should be guaranteed.
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Objectives: To investigate the trends in antibiotic resistance and antibiotic prescrip-
tion between 2007 and 2014 in the St. Petersburg State Medical University. MethOds: 
Data on patient demographics, length of stay in hospital, clinical outcomes, antibiotic 
usage and antibiotic susceptibility were retrospectively gathered for 3000 patients 
across 7 hospital wards between the years 2008 and 2014. Patients were eligible if 
they presented with or had any bacterial infection in hospital and had a microbio-
logical sample taken whilst in hospital. Across the same period, inpatient antibiotic 
prescriptions in the hospital pharmacy were gathered on a monthly basis and con-
verted into their defined daily dose (DDD) per 100 bed-days. Results: The most 
common infections were intra-abdominal (43%) and urinary tract (42%). Just over 
3,800 microbiological samples were collected over the study period for culture and 
susceptibility. Fourteen percent of these showed the isolated microorganism being 
resistant to the antibiotic it was tested against. This was highest in 2014 where the 
level of overall resistance reached 17%. The prevalence of extended spectrum beta-
lactamases (ESBLs) increased from 3% in 2008 to 11% in 2014. The data show that levels 
of Escherichia coli bacterial resistance doubled over the 7-year period from 11% to 22% 
with its resistance to ceftriaxone increasing from 2% in 2008 to 22% in 2014. Across 
the same time period the prescription of antibiotics, as measured by DDD, increased 
by 9.8%, with prescriptions of carbapenems increasing by 64%. cOnclusiOns: 
ers and specialists, hospital admissions within the last 12 months, and number of 
medications taken at least once a week. The results were presented according to 
age (in 5-year intervals), gender, education and subjective perception of income. 
Analyses of bivariate relationship dependency were performed by Pearson’s 
chi-square test and Cramer’s contingency coefficient, wherein the value of p < 
0.05 marked the significance level. Results: The analysis showed as intuitively 
expected that older individuals in Slovenia more often seek ambulatory medical 
care, take multiple medications and are hospitalized at a higher rate. The only 
exception was the oldest seniors (85+) group, in which we observed that the uti-
lization of health services was lower than in the age group from 70 to 79 years. 
Besides age, education was an important factor that influenced the use of health 
care services, while income significantly affected only the number of contacts with 
general practitioners. cOnclusiOns: Our findings are important as the basis for 
the planning and implementation of health care system in Slovenia, particularly 
in the current conditions of austerity measures, changing demographic structure 
and rapid technological progress of medicine.
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DEvELOPMEnT, TEST-RETEST RELIABILITY AnD vALIDITY OF THE PHARMACY 
vALUE ADDED SERvICES QUESTIOnnAIRE
Hoay TL1, Hassali MA2, Saleem F1, Gan V3
1Universiti Sains Malaysia, Penang, Malaysia, 2Universiti Sains Malaysia (USM), Pulau Pinang, 
Malaysia, 3Universiti Putra Malaysia, Serdang, Malaysia
Objectives: To establish reliability and validity of a Value Added Services 
Questionnaire (VASQ) using themes generated from interviews based on Theory 
of Planned Behaviour. MethOds: Using an extended Theory of Planned Behavior 
(TPB) as the theoretical model, face-to-face interviews generated salient beliefs 
of VAS. The VASQ questionnaire was constructed initially in English incorporat-
ing important themes and later translated into the Malay language with forward 
and backward translation. Intention (INT) to adopt VAS is predicted by Attitudes 
(ATT), Subjective Norms (SN), Perceived Behavioral Control (PBC), Knowledge and 
Expectations. Using a 7-point Likert-type scale and a dichotomous scale, test-
retest reliability (N = 25) was assessed by administrating the questionnaire instru-
ment twice at an interval of one week apart. Internal consistency was measured 
by Cronbach’s alpha and construct stability between two administrations was 
assessed using the kappa statistic and the Intraclass correlation coefficient (ICC). 
Confirmatory factor analysis (N = 410) was conducted to assess construct validity of 
the VASQ. Results: The kappa coefficients indicate a moderate to almost perfect 
strength of agreement between test and retest. The ICC for all scales tested for intra-
rater (test-retest) reliability was good . The overall Cronbach’ s alpha (N = 25) is 0.912 
and 0.908 for the two time points. The result of factor analysis (N = 410) showed 
most items loaded strongly and correctly into corresponding factors. Only one item 
is suggested to be eliminated. cOnclusiOns: This study is the first to develop 
and establish the reliability and validity of the Value Added Services Questionnaire 
instrument using the Theory of Planned Behaviour as the theoretical model. The 
translated Malay language version of VASQ is reliable and valid to predict Malaysian 
patients’ intention to adopt VAS to collect partial medicine supply.
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THE IMPACT OF COnSUMER-DIRECTED HEALTH PLAnS On PRICE SHOPPIng
Sood N1, Zhang X1, Wagner Z2, Mehrotra A3, Huckfeldt P4, Haviland A5
1University of Southern California, Los Angeles, CA, USA, 2UC Berkeley, Berkeley, CA, USA, 
3Harvard University, Boston, MA, USA, 4University of Minnesota, Minneapolis, MN, USA, 
5Carnegie Mellon University, Pittsburgh, PA, USA
Objectives: To evaluate whether consumer-directed health plans (CDHPs) lead 
patients to shop for lower-cost office visits. MethOds: We started by comparing 
the prices paid by patients in CDHPs versus traditional plans. However, this simple 
approach had two potential bias sources: 1) differences in negotiated prices between 
CDHPs and traditional plans and 2) difference in patients’ preferences for price shop-
ping. Therefore, we first examined the negotiated price difference within the same 
provider and then investigated the Pre- (and post-) CDHP enrollment patients’ price 
shopping behavior within the same plan and hospital referral region (Plan-HRR). 
Finally, we estimated the effect of CDHP enrollment under difference-in-difference 
(DID) frameworks. We used longitudinal claims data comparing patients switch-
ing from traditional plans in pre year to CDHPs in post year (treatment group) with 
patients remaining in traditional plans (control group). The outcomes were the total 
price on the patient level and the percentile of the price within a Plan-HRR. Results: 
CDHP patients paid higher price than controls, but even the same provider charged 
significantly higher price from CDHP patients (β = 1.959±0.112, P< 0.01). Prior to CDHP 
enrollment, patients in the treatment group paid slightly lower than the controls 
but not statistically significant (β = -0.528±0.328, P= 0.108). Post-enrollment adjusted 
price was significantly lower in the treatment group (β = -2.224±0.392, P< 0.01), which 
resulted in a slight but significant reduction in price paid by patients switching to 
CDHPs (price DID estimate: -1.697±0.504, P= 0.001; percentile of price DID estimate: 
-0.900±0.480, P= 0.061). Moreover, switching to CDHPs and simultaneously switching 
providers are associated with larger effects in price shopping relative to CDHP patients 
not switching providers, but the magnitude of the difference was small (price DID 
estimate: -2.188±0.605 vs. -0.491±0.462, P= 0.0045; percentile of price DID estimate: 
-1.631±0.592 vs. -0.130±0.452, P= 0.0151). cOnclusiOns: Switching to CDHPs does 
lead patients shop for lower-cost office visits but the savings are modest.
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A nEw METHODOLOgY TO DEFInE THE SCOPE OF THE FREnCH  
« LISTE-En-SUS »
Motte A, Mourlat B, Kujas P, Eliaszewicz M
French ministry of Health, Paris, France
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retrieved from the G-BA homepage (https://www.g-ba.de/informationen/nutzenbe-
wertung/). Cut-off date for assessment inclusion was May 15th 2015. The following 
sources for extraction had to be available: Dossier module 3 (pharmaceutical com-
panies), G-BA decision/rationale (G-BA). Extraction included assessment date/type, 
active substance, indication(s), therapeutic area, target population in total/subgroups 
(min, max, exact) and data sources. Missing exact numbers were calculated from min/
max. For the analysis indications/subgroups clearly differing by written definition 
were excluded. Results: 147 indications were included. Overall the mean devia-
tion for the target population was 39 % (exact number, positive/negative differences 
included). Mean deviations by year were 42 % (2011), 15 % (2012), 65 % (2013) and 35 
% (2014/2015). Therapeutic areas with the highest deviations concerned “Infectious 
Diseases” (110 %), “Metabolic Diseases” (51 %) and “Oncology” (28 %). These areas 
accounted for 9, 34 and 27 % of the 147 assessments, respectively. Further results on 
e.g. min/max, subgroups, sensitivity analyses excluding deviations ≥ 80 % (signaling 
a difference in definition) will be presented. cOnclusiOns: Epidemiological data 
presented by pharmaceutical companies and G-BA differs considerably. A learning 
curve from 2011 to 2014 is not clearly visible. Susceptible therapeutic areas with high 
deviations are infectious diseases, metabolic diseases and oncology. The poster will 
discuss possible reasons, including data sources.
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PRICES CHAngES FOR PATEnT-PROTECTED InnOvATIvE DRUgS In THE TOP 5 
EU PHARMACEUTICAL MARkETS
Reinaud F1, Ando G2
1IHS Life Sciences, Paris, France, 2IHS Life Sciences, London, UK
Objectives: Identify within the top 5 EU countries where innovative pharmaceuti-
cal prices decrease the most. MethOds: Average price changes over time as well as 
average time to first price cuts were analysed for pharmaceuticals approved by the 
European Medicines Agency (EMA), priced in each market in 2009 and afterwards, 
which are still patent-protected and reimbursed in all analysed markets. Results: 
Overall, the majority of the innovative drugs that are reimbursed and still patent-
protected have not experienced a price change in each of the market studied since 
2009. Over the period analysed, Germany and France are the countries where the 
largest number of innovative drugs experienced a price cut (around 37% of the 
samples analysed for both countries). Price cuts commonly occur after 1.2 year 
on average in Germany and 1.7 year in France. Drugs assessed under the AMNOG 
reform in Germany saw their prices drop by an average of 17%. In Italy, Spain and 
the United Kingdom, the part of innovative pharmaceuticals experiencing price 
cuts is more limited, 10.6%, 12.9% and 16.9%. Additionally, the average price cut is 
small. cOnclusiOns: Within the EU top 5, price cuts for innovative pharmaceuti-
cals are more likely to be implemented in Germany as well as in France. In Germany, 
the AMNOG reform has had a significant impact on prices of drugs that completed 
the process. In France, the majority of the price cuts occurred for drugs that are not 
deemed innovative (ASMR rating of IV or V); which are therefore not granted the 
European level price guarantee for a five-year period. In Italy, Spain and the United 
Kingdom, price cuts do not occur regularly, at least at the list level. Other studies 
have demonstrated that prices tend to be lower at launch but are more likely to 
remain constant over time.
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OUTPATIEnT UTILIzATIOn AnD QUALITY APPRAISAL OF AnTIBIOTICS In 
TURkEY
Demir C, Gursoy K, Ozturk Y, Koselerli R
Turkish Social Security Institution, Ankara, Turkey
Objectives: Antibiotic use is of great importance in terms of public health since 
misuse can result in antibiotic resistance. Therefore, evaluating antibiotic consump-
tion is essential. The objective of this study is to analyze the outpatient utiliza-
tion and measure the quality of antibiotic use in Turkey. MethOds: Data on the 
total outpatient consumption of antibacterials for systemic use (J01) from 2010 to 
2013 were aggregated from the Turkish Social Security Institution (SGK) at the level 
of active ingredient and then expressed in Defined Daily Doses (DDD) per 1000 
inhabitant per day according to WHO guideline. Annual growth rates of utilization 
were examined. Moreover, 5 of the ESAC Quality Indicators for Consumption of 
Antimicrobials for Systemic Use were computed according to ECDC Survelliance 
Report 2012. Results: While utilization in 2011 boosted by 28% and reached 37 
DDD per 1000 inhabitants per day mostly due to the new drug penetration to the 
market, the figure reduced to 35 in 2013, the highest among EU countries. J01C 
ATC-3 group received the largest share (43,5%) from the total J01 consumption, 
followed by J01D and J01F, all three constituting nearly 88%. As quality indicators, 
relative use of beta lactamase-sensitive penicillins (J01CE_%) and fluoroquinolones 
(J01MA_%) shrank in each year whereas the ratio of broad to narrow spectrum 
antibacterials rose from 11 in 2010 to 17,1 in 2013. Additionally, relative use of com-
binations of penicillins including beta-lactamase inhibitors (J01CR_%) and third 
and fourth-generation cephalosporins (J01DD+DE_%) reached to 37,5% and 13,3% 
respectively in 2013, all indicating misprescribing and hence leading to antibiotic 
resistance. cOnclusiOns: Compared to European countries, antibiotic consump-
tion in Turkey is quite high and there occurs a shift from narrow spectrum antibiot-
ics to broad ones. As a solution, rational drug use and prescription guidelines can 
be policy tools to reduce consumption and improve quality.
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THE IMPACT OF THE InCREASIng PEnETRATIOn OF On-PATEnT MEDICInES On 
THE gREEk PHARMACEUTICAL MARkET
Manias NG1, Kyriopoulos I2, Ollandezos M2, Athanasakis K2, Kyriopoulos J2
1MINTE, ATHENS, Greece, 2National School of Public Health, Athens, Greece
Objectives: From 2001 onwards, a wave of new innovative medicines has been 
introduced in the Greek pharmaceutical market. Based on this, the purpose of this 
study is to identify and quantify the effects of the increasing penetration of innova-
tive medicines on pharmaceutical spending in Greece during the period 2001-2014, 
Prevalence of antibiotic resistant bacteria has steadily increased over the 7-year 
period alongside that of antibiotic usage. Association between antibiotic resistance 
and clinical factors including antibiotic consumption, site of infection and severity of 
infection will be examined and a mathematical model predicting bacterial resistance, 
which controls for these factors, is being constructed.
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THE UnDER-RECOgnISED HUMAn AnD ECOnOMIC IMPACT OF CHROnIC 
RHInOSInUSITIS
Battaglia S1, Annoni E1, Hodge D2, Barnett G1
1Medtronic International Trading Sàrl, Tolochenaz, Switzerland, 2Medtronic Inc., Surgical 
Technologies, Jacksonville, FL, USA
Objectives: The impact of chronic rhinosinusitis (CRS) on healthcare resources, 
productivity and health-related quality of life (HRQoL) is under-recognized and the 
condition under-treated. The objective of this study was to identify the extent of 
the human and economic impact of CRS. MethOds: A comprehensive literature 
search of Medline and EMBASE (2000- January 2015) was performed. Eligibility crite-
ria included patient-reported CRS or a CRS diagnosis, retrospective and prospective 
designs. Abstracts or full text articles were systematically selected if they presented 
data for patients with a diagnosis of CRS, and search terms relevant to CRS, and 
its human and economic burden were applied. Results: The search yielded 786 
titles and ultimately 32 abstracts/articles met the eligibility criteria. People with CRS 
have significantly worse physical, emotional, mental and social HRQoL compared 
to the general population. They are also three times as likely to report their health 
as poor compared to those with another chronic condition, and among those with 
medically refractory CRS, 49% report anxiety/depression, while 31% report problems 
with usual daily activities. In addition, CRS is associated with a significant rise 
in costs due to an increased need for primary/secondary care, emergency room 
visits, and prescription refills. Comparatively, medically refractory CRS resulted 
in a significantly higher indirect cost than diabetes, migraine or severe asthma; 
the cost of lost productivity was estimated to be US$10,077 annually per patient in 
the US, and increased with severity. The longer the time delay between diagnosis 
and sinus surgery (SS), the greater the need for CRS-related visits and prescrip-
tions, rendering delayed SS economically inefficient. However, the cost of managing 
complications of SS (nasal bleeds and cerebrospinal fluid leaks) more than doubles 
the cost of the procedure itself. cOnclusiOns: Results consistently demonstrate 
that CRS imposes a substantial human and economic burden on patients and soci-
ety, especially medically refractory CRS.
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SYSTEMATIC REvIEw On USE OF ECOnOMIC EvIDEnCE In CLInICAL 
gUIDELInES
Aggarwal S1, Topaloglu H1, Kumar S2
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, 
USA
Objectives: The recent reforms and policy changes have increased the cost pres-
sures on all healthcare stakeholders, including clinical experts. In the past, clini-
cal guidelines were developed independent of cost or economic considerations. 
However, increasingly, more clinical guidelines are mentioning cost concerns and 
referring to economic data in new recommendations. The objective of this study 
was to analyze trends in the use of health economic information for developing 
clinical guidelines. MethOds: A systematic literature search was undertaken for 
the databases Pubmed, Embase, Biosis, Google Scholar, and Cochrane. The guidelines 
published between 2003-2015 were included. For guidelines which met the search 
criteria, data was collected for the name of the authors, indication, year of publi-
cation, country/region, and context of use of cost/economic evidence. Results: 
Sixteen clinical guidelines published between 2003-2015 met the inclusion criteria 
for specific mention of cost/economic evidence. More than 50% of these guidelines 
were published between 2006-2015. For indication, 3 out of 16 guidelines were for 
diabetes, while the rest were for different indications. In these16 guidelines “cost 
effectiveness” was mentioned 14 times, either referencing cost-effectiveness data 
or to mention the importance of such data for selecting treatment options. The 
guidelines commonly cite high cost of disease or high economic burden as one of 
the considerations for developing new recommendations (11 out of 16). Another 
term that was commonly used by these guidelines was “cost-benefit,” which was 
mentioned 5 times in these guidelines. Notably, QALY was rarely mentioned (1 out 
of 16 times) in these guidelines. cOnclusiOns: This analysis suggests that some 
clinical experts groups are increasingly showing willingness to use and incorporate 
health economic information for developing new recommendations. Findings from 
this study might aid drug and device manufacturers in understanding the context of 
use of such information and allow them to tailor their product development plans 
for generating such evidence.
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EPIDEMIOLOgICAL DATA PRESEnTED In gERMAn BEnEFIT ASSESSMEnTS – A 
COMPARISOn BETwEEn PHARMACEUTICAL COMPAnIES AnD g-BA
El Malahi Z, Hirsch R, Boehler Y
Cologne University of Applied Sciences, Leverkusen, Germany
Objectives: Dossiers for German benefit assessments on drugs require epidemio-
logical data. The number of statutory health insured patients in the target population 
is needed; basically the claimed number of patients with added benefit. This number 
is presented by pharmaceutical companies, evaluated/adapted during assessment 
and then included in G-BAs final decisions. The aim of this study is to compare the 
epidemiological data presented by companies and G-BA in order to assess deviations 
overall, by year and by therapeutic area. Time trends, susceptible therapeutic areas 
and possible reasons may be delineated. MethOds: All relevant documents were 
